| ID Source | ID |
|---|---|
| PubMed CID | 156413 |
| CHEMBL ID | 545315 |
| SCHEMBL ID | 2052123 |
| MeSH ID | M0576802 |
| Synonym |
|---|
| AC-2414 |
| chembl545315 , |
| HY-10367A |
| canertinib (dihydrochloride) |
| canertinib dihydrochloride |
| D03350 |
| canertinib dihydrochloride (usan) |
| 289499-45-2 |
| 2-propenamide, n-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride |
| pd 183805 |
| ci 1033 |
| canertinib dihydrochloride [usan] |
| 2-propenamide, n-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride |
| n-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride |
| pd-0183805 |
| pd-0183805-002b |
| canertinib hydrochloride |
| n-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride |
| A19399 |
| n-[4-[(3-chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride |
| unii-icj93x8x90 |
| icj93x8x90 , |
| canertinib hcl |
| AKOS015924656 |
| n-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride |
| CS-0263 |
| n-[4-(3-chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-yl)propoxy]quinazolin-6-yl]prop-2-enamide dihydrochloride |
| canertinib dihydrochloride [mi] |
| canertinib dihydrochloride [who-dd] |
| 2-propenamide, n-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride |
| n-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-2-propenamide dihydrochloride |
| AM20090674 |
| SCHEMBL2052123 |
| CI-103 , |
| Q-200787 |
| n-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| Q-101362 |
| n-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide dihydrochloride |
| mfcd09954112 |
| DTXSID80183143 |
| canertinib dihydrochloride salt |
| ci-1033, >=98% (hplc) |
| pd-183805 dihydrochloride |
| ci-1033 dihydrochloride |
| n-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide dihydrochloride |
| AS-75065 |
| canertinib(dihydrochloride) |
| 289499-45-2 (hcl) |
| n-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride |
| FT-0724289 |
| canertinib 2hcl |
| BCP01902 |
| HMS3295E05 |
| ci-1033 dihydrochloride;pd-183805 dihydrochloride |
| Q27280663 |
| n-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide;dihydrochloride |
| S0711 |
| EN300-19659633 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To establish the maximum tolerated dosage (MTD), the dose-limiting toxicities (DLTs), and pharmacokinetic parameters of CI-980, a novel tubulin binder, in children with solid tumors refractory to standard therapy." | ( Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. Baruchel, S; Bernstein, ML; Blaney, S; Devine, S; Markoglou, N; Moghrabi, A; Vietti, T; Wainer, IW; Williams, M; Winick, N, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "To establish the maximum tolerated dosage (MTD), the dose-limiting toxicities (DLTs), and pharmacokinetic parameters of CI-980, a novel tubulin binder, in children with solid tumors refractory to standard therapy." | ( Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. Baruchel, S; Bernstein, ML; Blaney, S; Devine, S; Markoglou, N; Moghrabi, A; Vietti, T; Wainer, IW; Williams, M; Winick, N, ) | 0.13 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0036 | 0.0000 | 0.5369 | 10.0000 | AID1315978; AID1315982; AID260895; AID260898; AID66611; AID66614; AID69562 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | IC50 (µMol) | 0.0132 | 0.0001 | 0.5453 | 10.0000 | AID1315979; AID1315981; AID260896; AID260899; AID260903; AID69713 |
| Insulin receptor | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0017 | 0.8479 | 10.0000 | AID260902 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0006 | 0.8007 | 8.5000 | AID260900 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0002 | 0.9420 | 10.0000 | AID260901 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0001 | 0.4912 | 10.0000 | AID260900 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0004 | 0.3276 | 8.6200 | AID260901 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0008 | 0.6217 | 8.6200 | AID260901 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0004 | 0.2863 | 8.6200 | AID260901 |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | IC50 (µMol) | 0.0290 | 0.0001 | 0.1736 | 2.5900 | AID1315980; AID260897 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | Kd | 5.8500 | 0.0002 | 0.8159 | 9.8000 | AID599957; AID599959 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (56.67) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 13 (41.94%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (58.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer [NCT00050830] | Phase 2 | 163 participants | Interventional | 2003-01-31 | Completed | ||
| A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer [NCT00051051] | Phase 2 | 168 participants | Interventional | 2002-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||